What is Entero Therapeutics, Inc. (GRDX) stock price today?

Entero Therapeutics, Inc. (GRDX) currently trades at $2.51 per share. The stock has a market capitalization of $7.56M and a P/E ratio of —x.

Is GRDX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Entero Therapeutics, Inc. has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -1.88.

Is Entero Therapeutics, Inc. financially healthy?

Entero Therapeutics, Inc.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -1.88 places it in the distress.

GRDX

Entero Therapeutics, Inc.

NASDAQ: GRDX · HEALTHCARE · BIOTECHNOLOGY

$2.51

+17.29% today

Updated 2026-04-30

Market cap

$7.56M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-11.66

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

Market cap

$7.56M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-11.66

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

4.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-1.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -1.88 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-855688.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-58.54M	$-14.63M	$-15.79M	$-18.06M	$-1.15M
EPS	—	—	—	—	$-11.66
Free cash flow	$-42.61M	$-22.34M	$-12.88M	$-9.22M	$-855688.00
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GRDX	$7.56M	27	4.3	4.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Entero Therapeutics, Inc. trades at $2.51. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.88, it sits in the distress.

Frequently asked questions

What is Entero Therapeutics, Inc.'s stock price?

Entero Therapeutics, Inc. (GRDX) trades at $2.51.

Is Entero Therapeutics, Inc. overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Entero Therapeutics, Inc. (GRDX)?

The analyst target price is $—, representing NaN% downside from the current price of $2.51.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-1.88 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.grid-ai.com

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$2.33

200D MA$2.95

Shares out0.00B

Float—

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GRDX vs LLY →GRDX vs JNJ →GRDX vs ABBV →Stock screener →